News and features

Lara Jukes is the Director of Development at The Institute of Cancer Research, London. As we thank generous donors to our Spring fundraising appeal, she reflects on why giving is an integral part of our culture and how much of a difference it can make to those who need it most.

Men with particularly aggressive prostate cancers can be treated more effectively by combining an existing targeted medicine, abiraterone, with a new experimental drug to block two of cancer’s growth signals at once, a major new trial shows.

Since its release in 2011, canSAR has become the largest, public, cancer drug discovery resource in the world. On the 10-year anniversary of canSAR we take a look at how it’s shaping the future of drug discovery.

An artificial intelligence (AI) that reconstructs MRI images of moving tumours can do so in seconds, offering a significant improvement on current methods to optimise radiotherapy treatment in the clinic.

A new study could lead to improved decision making in assigning treatments for children with the aggressive cancer rhabdomyosarcoma after revealing key genetic changes underlying development of the disease.

A new drug could become the first ever targeted brain cancer treatment, with encouraging early results from a phase 1 trial suggesting it could treat some patients with advanced disease.

Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumours have faulty copies of the BRCA cancer genes.

Professor Nick James and Professor Emma Hall were recognised for their contributions to radiology and oncology by the Royal College of Radiologists in a virtual admission ceremony today.

For our latest Discovery Club, members met virtually with some of our leading scientists, who are using cutting-edge methods to assess and treat rare cancers such as sarcoma and other cancers of unmet need. During the evening, guests learned more about how they helping to find new treatment options for these patients who desperately need them - and why philanthropic support is so vital.

Women with high-risk, early-stage breast cancer who also have inherited faults in their BRCA1 or BRCA2 genes have shown a remarkable response to the targeted drug olaparib in a major clinical trial.

A new high-tech drug treatment for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep patients alive and healthy for longer, a new phase III trial reports.

Professor Julia Buckingham CBE, an acclaimed medical researcher with exceptional leadership experience in academic institutions and across the sector, will become Chair of The Institute of Cancer Research, London, in August.